Analysts predict that NeoGenomics, Inc. (NASDAQ:NEO) will report earnings of $0.07 per share for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for NeoGenomics’ earnings. The highest EPS estimate is $0.09 and the lowest is $0.05. NeoGenomics reported earnings per share of $0.06 in the same quarter last year, which would suggest a positive year-over-year growth rate of 16.7%. The company is expected to issue its next earnings report on Tuesday, February 18th.
On average, analysts expect that NeoGenomics will report full-year earnings of $0.28 per share for the current financial year, with EPS estimates ranging from $0.26 to $0.30. For the next financial year, analysts anticipate that the firm will report earnings of $0.37 per share, with EPS estimates ranging from $0.33 to $0.42. Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow NeoGenomics.
NeoGenomics (NASDAQ:NEO) last released its quarterly earnings results on Tuesday, October 29th. The medical research company reported $0.07 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.06 by $0.01. The business had revenue of $104.70 million during the quarter, compared to the consensus estimate of $99.38 million. NeoGenomics had a return on equity of 4.60% and a net margin of 0.55%. The business’s quarterly revenue was up 51.5% compared to the same quarter last year. During the same period in the previous year, the company posted $0.05 EPS.
In other news, Director Steven C. Jones sold 40,737 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $25.02, for a total transaction of $1,019,239.74. Following the completion of the transaction, the director now directly owns 245,234 shares in the company, valued at $6,135,754.68. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider George Cardoza sold 51,556 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $22.82, for a total value of $1,176,507.92. Following the transaction, the insider now owns 356,387 shares of the company’s stock, valued at $8,132,751.34. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 363,399 shares of company stock valued at $8,822,819. 8.80% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently modified their holdings of the company. NEXT Financial Group Inc raised its holdings in NeoGenomics by 200.0% during the second quarter. NEXT Financial Group Inc now owns 2,700 shares of the medical research company’s stock worth $59,000 after purchasing an additional 1,800 shares in the last quarter. Captrust Financial Advisors purchased a new position in NeoGenomics during the 2nd quarter worth approximately $66,000. Nisa Investment Advisors LLC grew its position in NeoGenomics by 867.5% during the 3rd quarter. Nisa Investment Advisors LLC now owns 3,870 shares of the medical research company’s stock worth $74,000 after purchasing an additional 3,470 shares in the last quarter. Benjamin F. Edwards & Company Inc. grew its position in NeoGenomics by 75.0% during the 3rd quarter. Benjamin F. Edwards & Company Inc. now owns 4,550 shares of the medical research company’s stock worth $87,000 after purchasing an additional 1,950 shares in the last quarter. Finally, Winslow Evans & Crocker Inc. purchased a new position in NeoGenomics during the 2nd quarter worth approximately $92,000. Institutional investors and hedge funds own 84.48% of the company’s stock.
NASDAQ:NEO traded up $0.16 during mid-day trading on Friday, reaching $23.06. The stock had a trading volume of 7,109 shares, compared to its average volume of 669,673. The company has a market capitalization of $2.36 billion, a price-to-earnings ratio of 178.31 and a beta of 0.94. NeoGenomics has a 1-year low of $11.05 and a 1-year high of $26.89. The stock’s 50 day simple moving average is $20.71 and its two-hundred day simple moving average is $22.55. The company has a debt-to-equity ratio of 0.24, a current ratio of 4.24 and a quick ratio of 4.05.
NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.
Recommended Story: Correction
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.